Cara Therapeutics Files 8-K

TL;DR

Cara Therapeutics filed an 8-K on 12/30/24 for corporate updates and financials.

AI Summary

Cara Therapeutics, Inc. filed an 8-K on December 30, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements and exhibits. The filing does not contain specific financial figures or details about the amendments.

Why It Matters

This filing indicates administrative updates and the submission of financial information, which are standard corporate disclosures.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for corporate and financial disclosures, not indicating any immediate material events.

Key Players & Entities

• Cara Therapeutics, Inc. (company) — Registrant
• December 30, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke

Filing Documents

• tm2430195d4_8k.htm (8-K) — 34KB
• tm2430195d4_ex3-1.htm (EX-3.1) — 11KB
• 0001104659-24-132481.txt ( ) — 223KB
• cara-20241230.xsd (EX-101.SCH) — 3KB
• cara-20241230_lab.xml (EX-101.LAB) — 33KB
• cara-20241230_pre.xml (EX-101.PRE) — 22KB
• tm2430195d4_8k_htm.xml (XML) — 4KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. (a) Amendment of Amended and Restated Certificate of Incorporation to Effect Reverse Stock Split and Shares Reduction On December 30, 2024, Cara Therapeutics, Inc. (the " Company ") filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the " Amendment ") with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split (the " Reverse Stock Split ") of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 (the " Shares Reduction "). The Amendment will be effective at 5:00 p.m. Eastern Time on December 30, 2024. A series of alternate amendments to effect (i) a reverse stock split and (ii) a reduction in the total number of authorized shares of the Company's common stock was approved by the Company's stockholders at the Company's 2024 Annual Meeting of Stockholders held on June 4, 2024, and the specific one-for-twelve (1-for-12) Reverse Stock Split and corresponding Shares Reduction was subsequently approved by the Company's board of directors on December 19, 2024. The Amendment provides that, at the effective time of the Amendment, every twelve (12) shares of the Company's issued and outstanding common stock will automatically be combined into one (1) issued and outstanding share of common stock and the authorized shares of the Company's common stock will reduce from 200,000,000 to 16,666,667, without any change in par value per share. The Reverse Stock Split will affect all shares of the Company's common stock outstanding immediately prior to the effective time of the Amendment. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options issued by the Company and outstanding immedia

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., effective December 30, 2024. 104 Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer Date: December 30, 2024

View Full Filing

View this 8-K filing on SEC EDGAR